17952-63-5

Usage

Uses

Used in Staining and Dyeing Applications:
6-METHOXY-1 2 3 4-TETRAHYDRO-9H-PYRIDO-& is used as a stain/dye for its ability to impart color to various materials. The compound's chemical structure allows it to bind with other molecules, making it an effective coloring agent in different industries.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, 6-METHOXY-1 2 3 4-TETRAHYDRO-9H-PYRIDO-& is used as a metabolite for research and development purposes. Its unique chemical properties make it a valuable compound for studying various biological processes and developing new drugs.
Used in Research and Development:
6-METHOXY-1 2 3 4-TETRAHYDRO-9H-PYRIDO-& is also used in research and development for its potential applications in various fields. Its chemical properties and reactivity make it an interesting subject for further study and potential use in the development of new materials, compounds, or processes.

InChI:InChI=1/C13H14N2O3/c1-18-7-2-3-10-9(6-7)8-4-5-14-12(13(16)17)11(8)15-10/h2-3,6,12,14-15H,4-5H2,1H3,(H,16,17)

Upstream product

• 66-83-1 5-methoxytryptamine hydrochloride 
• 298-12-4 Glyoxilic acid 
• 608-07-1 2-(5-methoxyindol-3-yl)ethylamine 

Downstream Products

• 20315-68-8 pinoline 
• 88704-49-8 eudistomin Q 
• 88704-39-6 eudistomin M 
• 58982-28-8 6-Hydroxy-beta-Carboline 

Relevant academic research and scientific papers

Peganumine A alkaloid structure simplifier and application thereof

The invention discloses a Peganumine A alkaloid structure simplifier, a stereoisomer or a pharmaceutical salt thereof. The structure is shown in the following general formula: each substituent group is defined in the specification. The simplified structure of the Peganumine A alkaloid provided by the invention has a relatively obvious proliferation inhibition effect on liver cancer HepG2, lung cancer A549 and intestinal cancer HCT116, and the anti-tumor activity of part of compounds is higher than the anti-liver cancer HepG2 activity of Peganumine A reported in literatures.

First total synthesis of the β-carboline alkaloids trigonostemine A, trigonostemine B and a new synthesis of pityriacitrin and hyrtiosulawesine

The total synthesis of four natural products, trigonostemine A, trigonostemine B, pityriacitrin, and hyrtiosulawesine was accomplished. The key intermediates, variously substituted 1-formyl-β-carbolines, were prepared in five steps via a novel synthetic approach using readily available starting materials. These formyl derivatives were then further transformed, providing a general route for the synthesis of the four title alkaloids. The method reported herein represents the first total synthesis of the two trigonostemines and a new pathway to pityriacitrin and hyrtiosulawesine.

6-Hydroxy- and 6-methoxy-β-carbolines as acetyl- and butyrylcholinesterase inhibitors

In the course of studies directed toward the discovery of novel acetyl- and butyrylcholinesterase (AChE and BChE) inhibitors for the treatment of Alzheimer's disease, we focused on β-carbolines (BCs). 6-Oxygenated β-carboline and β-carbolinium derivatives based on the serotonin template were synthesized and tested in vitro for their ability to inhibit AChE and BChE, respectively. Particularly the carbolinium salts, which can be formed by intracerebral methylation out of the tertiary-BC prodrugs, show inhibitory activity levels reaching those of galantamine, physostigmine, and rivastigmine.

Use of derivatives of tetrahydro-beta-carbolines as antimetastatic agents

PCT No. PCT/EP97/01582 Sec. 371 Date Nov. 12, 1998 Sec. 102(e) Date Nov. 12, 1998 PCT Filed Mar. 27, 1997 PCT Pub. No. WO97/37658 PCT Pub. Date Oct. 16, 1997The present invention concerns the use of beta-carboline derivatives of formula I bearing at least a free or esterified carboxylic group on the piperidine ring, for the preparation of pharmaceutical compositions having antimetastatic properties.